{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:09:02Z","timestamp":1777918142835,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[1982,8,1]],"date-time":"1982-08-01T00:00:00Z","timestamp":397008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[1982,8]]},"abstract":"<jats:p>\n                    We conducted a phase II trial of Vindesine in 24 patients, mostly pretreated (23\/24 fully evaluable for therapeutic response) with advanced hematologic malignancies. The drug was administered at weekly bolus doses of 3 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    i.v. Overall, objective tumor regressions were seen in 9 of 23 patients. The drug appeared effective in extraosseous plasmacytoma (1 complete response and 1 minor response in 3 patients) and in mycosis fungoides (1 complete response, 1 partial response and 1 minor response in 6 patients). Further phase II trials in these 2 diseases are justified. In addition, 3 partial responses in 7 patients with advanced lymphoma were also obtained. Previous vinca-alkaloid exposure did not adversely affect the response rate: 8 of 9 responsive patients had previously received vincristine and\/or vinblastine. Drug-related toxic effects were mainly represented by manageable and reversible neurotoxicity and by moderate leukopenia with apparent lack of thrombocytopenia. In heavily pretreated patients, leukopenia may be occasionally severe: in these conditions a starting dose of 2 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    seems more appropriate.\n                  <\/jats:p>","DOI":"10.1177\/030089168206800409","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T12:22:14Z","timestamp":1523881334000},"page":"321-324","source":"Crossref","is-referenced-by-count":0,"title":["Phase II Evaluation of Vindesine in Mycosis Fungoides, Extraosseous Plasmacytoma and other Hematologic Malignancies"],"prefix":"10.1177","volume":"68","author":[{"given":"Eros","family":"Ferrazzi","sequence":"first","affiliation":[{"name":"Divisione di Oncologia Medica, Ospedale Civile, Padova e, Ospedale Civile, Pordenone"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni L.","family":"Pappagallo","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica, Ospedale Civile, Padova e, Ospedale Civile, Pordenone"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romana","family":"Segati","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica, Ospedale Civile, Padova e, Ospedale Civile, Pordenone"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orazio","family":"Vinante","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica, Ospedale Civile, Padova e, Ospedale Civile, Pordenone"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Galligioni","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica e Radioterapia, Ospedale Civile, Pordenone"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica e Radioterapia, Ospedale Civile, Pordenone"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Salvagno","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica, Ospedale Civile, Padova e, Ospedale Civile, Pordenone"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario V.","family":"Fiorentino","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica, Ospedale Civile, Padova e, Ospedale Civile, Pordenone"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1982,8,1]]},"reference":[{"key":"bibr1-030089168206800409","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257189"},{"key":"bibr2-030089168206800409","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257192"},{"key":"bibr3-030089168206800409","first-page":"174","volume":"17","author":"Currie V.","year":"1976","journal-title":"Proc. Am. Ass. Cancer Res., and ASCO"},{"key":"bibr4-030089168206800409","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(77)80010-8"},{"key":"bibr5-030089168206800409","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257185"},{"key":"bibr6-030089168206800409","first-page":"176","volume":"3","author":"Gianni L.","year":"1980","journal-title":"Chemioter. Oncol."},{"key":"bibr7-030089168206800409","first-page":"1343","volume":"63","author":"Gralla R.J.","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"bibr8-030089168206800409","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257194"},{"key":"bibr9-030089168206800409","first-page":"1331","volume":"2","author":"Krivit W.","year":"1978","journal-title":"Curr. Chemother."},{"key":"bibr10-030089168206800409","first-page":"805","volume":"62","author":"Math\u00e9 G.","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"bibr11-030089168206800409","first-page":"1001","volume":"64","author":"Miller T.P.","year":"1980","journal-title":"Cancer Treat. Rep."},{"key":"bibr12-030089168206800409","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257190"},{"key":"bibr13-030089168206800409","first-page":"2063","volume":"63","author":"Sklaroff R.B.","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"bibr14-030089168206800409","first-page":"793","volume":"63","author":"Sklaroff R.B.","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"bibr15-030089168206800409","first-page":"1427","volume":"62","author":"Smith I.C.","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"bibr16-030089168206800409","first-page":"2886","volume":"38","author":"Sweeney M.J.","year":"1978","journal-title":"Cancer Res."},{"key":"bibr17-030089168206800409","first-page":"877","volume":"65","author":"Valdivieso M.","year":"1981","journal-title":"Cancer Treat. Rep."}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089168206800409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089168206800409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:31:47Z","timestamp":1777660307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089168206800409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1982,8]]}},"alternative-id":["10.1177\/030089168206800409"],"URL":"https:\/\/doi.org\/10.1177\/030089168206800409","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,8]]}}}